PL2984184T3 - Stosowanie DNQ lub DNQ-87 w połączeniu z inhibitorem PARP1 do leczenia nowotworu - Google Patents
Stosowanie DNQ lub DNQ-87 w połączeniu z inhibitorem PARP1 do leczenia nowotworuInfo
- Publication number
- PL2984184T3 PL2984184T3 PL14783210T PL14783210T PL2984184T3 PL 2984184 T3 PL2984184 T3 PL 2984184T3 PL 14783210 T PL14783210 T PL 14783210T PL 14783210 T PL14783210 T PL 14783210T PL 2984184 T3 PL2984184 T3 PL 2984184T3
- Authority
- PL
- Poland
- Prior art keywords
- dnq
- cancer
- treatment
- combination
- parp1 inhibitor
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 101150063226 parp-1 gene Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/131—Amines acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361810008P | 2013-04-09 | 2013-04-09 | |
| EP14783210.9A EP2984184B1 (en) | 2013-04-09 | 2014-04-08 | Use of dnq or dnq-87 in combination with a parp1 inhibitor for the treatment of cancer |
| PCT/US2014/033400 WO2014168991A1 (en) | 2013-04-09 | 2014-04-08 | Tumor-selective combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2984184T3 true PL2984184T3 (pl) | 2021-06-14 |
Family
ID=51689971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14783210T PL2984184T3 (pl) | 2013-04-09 | 2014-04-08 | Stosowanie DNQ lub DNQ-87 w połączeniu z inhibitorem PARP1 do leczenia nowotworu |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10272099B2 (pl) |
| EP (1) | EP2984184B1 (pl) |
| JP (2) | JP6615746B2 (pl) |
| CN (2) | CN111481551B (pl) |
| AU (2) | AU2014251043B2 (pl) |
| BR (1) | BR112015025662A2 (pl) |
| CA (1) | CA2909091C (pl) |
| DK (1) | DK2984184T3 (pl) |
| ES (1) | ES2853973T3 (pl) |
| HU (1) | HUE052930T2 (pl) |
| MX (2) | MX2015014282A (pl) |
| PL (1) | PL2984184T3 (pl) |
| PT (1) | PT2984184T (pl) |
| WO (1) | WO2014168991A1 (pl) |
| ZA (1) | ZA201507755B (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014251043B2 (en) * | 2013-04-09 | 2020-01-16 | The Board Of Regents Of The University Of Texas System | Tumor-selective combination therapy |
| US20200179417A1 (en) * | 2016-06-27 | 2020-06-11 | Systems Oncology, Llc | Combination chemotherapies |
| WO2019113345A1 (en) * | 2017-12-06 | 2019-06-13 | Spyro Mousses | Combination of cancer therapeutics for treatment of cancer and hyperproliferative diseases |
| WO2019156684A1 (en) * | 2018-02-12 | 2019-08-15 | Solugen, Inc. | Hydrogen peroxide production method, system, and apparatus |
| WO2019194738A1 (en) | 2018-04-05 | 2019-10-10 | Noviga Research Ab | Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer |
| JP7447013B2 (ja) * | 2018-04-09 | 2024-03-11 | ユンジン ファーム.カンパニー、リミテッド | 1,2-ナフトキノン誘導体化合物を含む固形癌または血液癌の予防または治療用薬学組成物 |
| EP3942061A4 (en) * | 2019-03-18 | 2022-12-14 | The Board Of Regents Of The University Of Texas System | TUMOR SELECTIVE COMBINATION THERAPY |
| WO2025047770A1 (ja) * | 2023-08-31 | 2025-03-06 | 東レ株式会社 | デオキシニボキノン誘導体の製造方法 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4906562A (en) * | 1984-12-21 | 1990-03-06 | Oncogen | Monocolonal antibodies and antigen for human non-small cell lung carcinomas |
| ES2088822B1 (es) * | 1994-02-24 | 1997-08-01 | Univ Madrid Complutense | Nuevos derivados antraquinonicos con actividad antitumoral y sus aplicaciones. |
| US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
| US6635677B2 (en) * | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| FR2797446B1 (fr) * | 1999-08-13 | 2001-11-02 | Lafon Labor | Derives de phenanthroline-7-ones et leurs applications en therapeutique |
| KR100957516B1 (ko) * | 2001-08-15 | 2010-05-14 | 이코스 코포레이션 | 2h-프탈라진-1-온 및 이것의 사용 방법 |
| MXPA04010199A (es) * | 2002-04-15 | 2005-07-05 | Sloan Kettering Inst Cancer | Terapia en combinacion para el tratamiento de cancer. |
| AU2003228666A1 (en) | 2002-04-23 | 2003-11-10 | Case Western Reserve University | Lapachone delivery systems, compositions and uses related thereto |
| EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
| US8614228B2 (en) * | 2004-08-11 | 2013-12-24 | Arqule, Inc. | Quinone prodrug compositions and methods of use |
| WO2006024545A1 (en) * | 2004-09-03 | 2006-03-09 | Stichting Voor De Technische Wetenschappen | Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes |
| WO2007092964A1 (en) * | 2006-02-09 | 2007-08-16 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment by using e09 and propylene glycol |
| BRPI0722053A2 (pt) | 2006-12-29 | 2018-04-17 | Tracon Pharmaceuticals Inc | método para o tratamento de câncer, formulação anticâncer, método de uso da formulação, e, uso de metoxiamina |
| KR20100102609A (ko) * | 2007-11-12 | 2010-09-24 | 바이파 사이언스 인코포레이티드 | Parp 억제제를 단독으로 사용하거나 항종양제와 병용하여 유방암을 치료하는 방법 |
| KR20100112192A (ko) * | 2008-02-04 | 2010-10-18 | 바이파 사이언스 인코포레이티드 | Parp-매개된 질병을 진단 및 치료하는 방법 |
| CA2791680A1 (en) * | 2010-03-01 | 2011-09-09 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| EP2558866B1 (en) | 2010-04-15 | 2016-08-17 | Tracon Pharmaceuticals, Inc. | Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors |
| US9081428B2 (en) * | 2010-04-23 | 2015-07-14 | Psion Inc. | Apparatus and method for impact resistant touchscreen display module |
| CN106978480A (zh) * | 2010-09-15 | 2017-07-25 | 阿尔玛克诊断有限公司 | 用于癌症的分子诊断试验 |
| DK2619331T3 (en) * | 2010-09-22 | 2018-06-06 | Univ Texas | METHODS OF CANCER TREATMENT COMPREHENSIVE TO TARGET NQO1 |
| US20120142650A1 (en) * | 2010-12-07 | 2012-06-07 | John Hollingsworth | Method for treating lung disease |
| US20120208767A1 (en) * | 2011-02-14 | 2012-08-16 | University Of Maryland, Baltimore | Method to Detect or Treat Painful Bladder Syndrome based on Relation to Quinone Oxidoreductase 1 |
| EP2568139B1 (en) * | 2011-09-12 | 2016-07-13 | Cummins Emission Solutions, Inc. | Integrated connection device for connecting several sensors |
| US9233960B2 (en) | 2011-10-14 | 2016-01-12 | The Board Of Trustees Of The University Of Illinois | Compounds and anti-tumor NQO1 substrates |
| AU2014251043B2 (en) * | 2013-04-09 | 2020-01-16 | The Board Of Regents Of The University Of Texas System | Tumor-selective combination therapy |
-
2014
- 2014-04-08 AU AU2014251043A patent/AU2014251043B2/en not_active Ceased
- 2014-04-08 CN CN202010133652.8A patent/CN111481551B/zh active Active
- 2014-04-08 PL PL14783210T patent/PL2984184T3/pl unknown
- 2014-04-08 CN CN201480026213.XA patent/CN105658809B/zh active Active
- 2014-04-08 MX MX2015014282A patent/MX2015014282A/es unknown
- 2014-04-08 EP EP14783210.9A patent/EP2984184B1/en active Active
- 2014-04-08 BR BR112015025662A patent/BR112015025662A2/pt not_active IP Right Cessation
- 2014-04-08 CA CA2909091A patent/CA2909091C/en active Active
- 2014-04-08 WO PCT/US2014/033400 patent/WO2014168991A1/en not_active Ceased
- 2014-04-08 US US14/783,344 patent/US10272099B2/en active Active
- 2014-04-08 JP JP2016507622A patent/JP6615746B2/ja not_active Expired - Fee Related
- 2014-04-08 PT PT147832109T patent/PT2984184T/pt unknown
- 2014-04-08 DK DK14783210.9T patent/DK2984184T3/da active
- 2014-04-08 HU HUE14783210A patent/HUE052930T2/hu unknown
- 2014-04-08 ES ES14783210T patent/ES2853973T3/es active Active
-
2015
- 2015-10-09 MX MX2021000828A patent/MX2021000828A/es unknown
- 2015-10-16 ZA ZA201507755A patent/ZA201507755B/en unknown
-
2017
- 2017-12-06 US US15/834,052 patent/US10576096B2/en active Active
-
2019
- 2019-05-28 JP JP2019099014A patent/JP6719620B2/ja active Active
-
2020
- 2020-04-09 AU AU2020202453A patent/AU2020202453B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020202453B2 (en) | 2022-04-14 |
| ZA201507755B (en) | 2019-11-27 |
| EP2984184B1 (en) | 2020-11-25 |
| JP6719620B2 (ja) | 2020-07-08 |
| US10576096B2 (en) | 2020-03-03 |
| AU2014251043B2 (en) | 2020-01-16 |
| MX2021000828A (es) | 2021-03-25 |
| JP2016516775A (ja) | 2016-06-09 |
| WO2014168991A1 (en) | 2014-10-16 |
| CN111481551A (zh) | 2020-08-04 |
| DK2984184T3 (da) | 2021-03-01 |
| CA2909091A1 (en) | 2014-10-16 |
| ES2853973T3 (es) | 2021-09-20 |
| CA2909091C (en) | 2021-11-02 |
| JP2019163309A (ja) | 2019-09-26 |
| BR112015025662A2 (pt) | 2017-07-18 |
| HUE052930T2 (hu) | 2021-05-28 |
| AU2020202453A1 (en) | 2020-05-28 |
| AU2014251043A1 (en) | 2015-11-05 |
| CN111481551B (zh) | 2023-06-09 |
| US10272099B2 (en) | 2019-04-30 |
| MX2015014282A (es) | 2016-07-20 |
| PT2984184T (pt) | 2021-02-24 |
| US20180099002A1 (en) | 2018-04-12 |
| JP6615746B2 (ja) | 2019-12-04 |
| EP2984184A4 (en) | 2016-11-30 |
| US20160030457A1 (en) | 2016-02-04 |
| CN105658809A (zh) | 2016-06-08 |
| CN105658809B (zh) | 2020-03-27 |
| EP2984184A1 (en) | 2016-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL304851A (en) | Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer | |
| IL268094B (en) | History of heterocyclic compounds for use in the treatment of lung cancer | |
| GB2516814B (en) | Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| LT3033086T (lt) | Kombinuota terapija vėžiui gydyti | |
| SG11201509012QA (en) | Sobetirome in the treatment of myelination diseases | |
| IL242483B (en) | Preparations containing omomyc and their use for cancer treatment | |
| HUE052930T2 (hu) | DNQ vagy DNQ-87 alkalmazása PARP1-inhibitorral kombinációban rák kezelésére | |
| IL244353A0 (en) | Compounds and use for cancer treatment | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| EP2983648A4 (en) | COMBINATION THERAPEUTIC NANOPARTICLES | |
| ZA201607581B (en) | Dosage forms and therapeutic uses l-4lchlorokynurenine | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| LT2872176T (lt) | Karboranilporfirinai, skirti naudoti vėžio gydymui | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| SMT201900676T1 (it) | Arginina e/o citrullina per uso nel trattamento e/o nella prevenzione dell'artrosi | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| SI2857023T1 (sl) | Uporaba odiparcila za zdravljenje mukopolisaharidoze | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201307677D0 (en) | Compounds and their therapeutic use | |
| GB201312129D0 (en) | Drug combination and its use in therapy | |
| GB201312131D0 (en) | Drug combination and its use in therapy | |
| GB201312128D0 (en) | Drug combination and its use in therapy | |
| GB201314623D0 (en) | Novel mucinase for use in therapy or prophylaxis |